| Literature DB >> 27288771 |
YanBing Hou1, ChunYan Luo1, Jing Yang1, RuWei Ou1, Wei Song1, QianQian Wei1, Bei Cao1, Bi Zhao1, Ying Wu1, Hui-Fang Shang2, QiYong Gong3.
Abstract
Neuroimaging holds the promise that it may one day aid the clinical assessment. However, the vast majority of studies using resting-state functional magnetic resonance imaging (fMRI) have reported average differences between Parkinson's disease (PD) patients and healthy controls, which do not permit inferences at the level of individuals. This study was to develop a model for the prediction of PD illness severity ratings from individual fMRI brain scan. The resting-state fMRI scans were obtained from 84 patients with PD and the Unified Parkinson's Disease Rating Scale-III (UPDRS-III) scores were obtained before scanning. The RVR method was used to predict clinical scores (UPDRS-III) from fMRI scans. The application of RVR to whole-brain resting-state fMRI data allowed prediction of UPDRS-III scores with statistically significant accuracy (correlation=0.35, P-value=0.001; mean sum of squares=222.17, P-value=0.002). This prediction was informed strongly by negative weight areas including prefrontal lobe and medial occipital lobe, and positive weight areas including medial parietal lobe. It was suggested that fMRI scans contained sufficient information about neurobiological change in patients with PD to permit accurate prediction about illness severity, on an individual subject basis. Our results provided preliminary evidence, as proof-of-concept, to support that fMRI might be possible to be a clinically useful quantitative assessment aid in PD at individual level. This may enable clinicians to target those uncooperative patients and machines to replace human for a more efficient use of health care resources.Entities:
Keywords: Parkinson's disease; Prediction; Relevance vector regression; Resting-state functional magnetic resonance imaging
Mesh:
Year: 2016 PMID: 27288771 DOI: 10.1016/j.jns.2016.04.030
Source DB: PubMed Journal: J Neurol Sci ISSN: 0022-510X Impact factor: 3.181